An overview of clinical studies in healthy subjects and patients with severe sepsis with IC14, a CD14-specific chimeric monoclonal antibody

Journal of Endotoxin Research

Volumn 9, Issue 6, 2003, Pages 385-389

  Axtelle, Tim ^a   Pribble, John ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CD14 ANTIGEN; CEFTAZIDIME; CHIMERIC ANTIBODY; LIPOPOLYSACCHARIDE; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY IC14; PLACEBO; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; CLINICAL STUDY; CLINICAL TRIAL; DATA ANALYSIS; DISEASE SEVERITY; DRUG ANTIGENICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLAMMATION; MEMBRANE BINDING; NONHUMAN; NORMAL HUMAN; ORGAN; PHASE 1 CLINICAL TRIAL; PROVOCATION TEST; REVIEW; SEPSIS; SUPERINFECTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD14; CLINICAL TRIALS; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; RECOMBINANT FUSION PROTEINS; SEPSIS; TREATMENT OUTCOME;

EID: 0347028377     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805103225003321     Document Type: Review

References (24)

1. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski B, Golenbock D. Recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999; 163: 1-5.
2. Wright SD. CD14 and the innate response to bacteria, J Immunol 1995; 155: 6-8.
3. Beutler B, Poltorak A. Sepsis and the evolution of the innate immune response. Crit Care Med 2001; 29: S2-6-S6-7.
4. Pugin J, Heumann D, Tomasz A et al. CD14 is a pattern recognition receptor. Immunity 1994; 1: 509-516.
5. Takeuchi O, Hoshino K, Kawai T et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999; 11: 443-451.
6. Stelter F, Bernheiden M, Menzel R et al. The molecular basis for therapeutic concepts utilizing CD14. Prog Clin Biol Res 1998; 397: 301-313.
7. Mukaida N, Ishikawa Y, Ikeda N et al. Novel insight into molecular mechanism of endotoxin shock: biochemical analysis of LPS receptor signaling in a cell-free system targeting NR-kappa B and regulation of cytokine production/action through beta2 integrin in vivo. J Leukoc Biol 1996; 59: 145-151.
8. Oberholzer A, Oberholzer C, Moldawer L. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 2001; 16: 83-96.
9. Schimke J, Mathison J, Morgiewicz J, Ulevitch RJ. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl Acad Sci USA 1998; 95: 13875-13880.
10. Leturcq DJ, Moriarty AM, Talbott G et al. Antibodies against CD14 protects primates from endotoxin-induced shock. J Clin Invest 1996; 98: 1533-1538.
11. Frevert CW, Matute-Bello G, Skerrett SJ et al. Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis. J Immunol 2000; 164: 5439-5445.
12. Wenneras C, Ave P, Huerre M et al. Blockade of CD14 aggravates experimental shigellosis. J Endotoxin Res 2001; 7: 442-446.
13. Haziot A, Hijiya N, Gangloff SC, Silver J, Goyert SM. Induction of a novel mechanism of accelerated bacterial clearance by lipopolysaccharide in CD14-deficient and Toll-like receptor 4-deficient mice. J Immunol 2001; 166: 1075-1078.
14. Opal SM, Palardy JE, Parejo N, Jasman RL. Effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia. Crit Care Med 2003; In press.
15. Verbon A, Dekkers PDP, ten Hove T et al. IC14, and anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166: 3599-3605.
16. Axtelle T, Pribble J. IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res 2001; 7: 310-314
17. Olszyna DP, Verbon A, Pribble J et al. IC14, an anti-CD14 antibody, inhibits rises in plasma and cell-associated chemokines in human endotoxemia. Abstract 40th ICAAC Meeting, 2000.
18. Verbon A, Meijers JCM, Spek A et al. IC14, an anti-CD14 antibody, inhibits endotoxin induced fibrinolysis in humans without influencing coagulation activation. Abstract 41st ICAAC Meeting, 2001.
19. Reinhart K, Glueck T, Ligtenberg J et al. Phase 1 study of a recombinant chimeric monoclonal antibody against human CD14 (IC14) in patients with severe sepsis. Crit Care Med 2001; 29: A19.
20. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
21. Burgmann H, Winkler S, Locker GJ et al. Increased serum concentration of soluble CD14 is a prognostic marker in Gram-positive sepsis. Clin Immunol Immunopathol 1996; 80: 307-310.
22. Endo S, Inada K, Kasai T et al. Soluble CD14 (sCD14) levels in patients with multiple organ failure (MOF). Res Commun Chem Pathol Pharmacol 1994; 84: 17-25.
23. Haziot A, Rong G, Lin X, Silver J, Goyert S. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995; 154: 6529-6532.
24. Gluck T, Silver J, Epstein M, Cao P, Farber B, Goyert S. Parameters influencing membrane CD14 expression and soluble CD14 levels in sepsis. Eur J Med Res 2001; 6: 351-358.